Correlation Between Blueprint Medicines and Biomarin Pharmaceutical
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Biomarin Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Biomarin Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Biomarin Pharmaceutical, you can compare the effects of market volatilities on Blueprint Medicines and Biomarin Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Biomarin Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Biomarin Pharmaceutical.
Diversification Opportunities for Blueprint Medicines and Biomarin Pharmaceutical
-0.15 | Correlation Coefficient |
Good diversification
The 3 months correlation between Blueprint and Biomarin is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Biomarin Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomarin Pharmaceutical and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Biomarin Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomarin Pharmaceutical has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Biomarin Pharmaceutical go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Biomarin Pharmaceutical
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 0.98 times more return on investment than Biomarin Pharmaceutical. However, Blueprint Medicines Corp is 1.02 times less risky than Biomarin Pharmaceutical. It trades about 0.03 of its potential returns per unit of risk. Biomarin Pharmaceutical is currently generating about -0.19 per unit of risk. If you would invest 9,253 in Blueprint Medicines Corp on August 31, 2024 and sell it today you would earn a total of 257.00 from holding Blueprint Medicines Corp or generate 2.78% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Blueprint Medicines Corp vs. Biomarin Pharmaceutical
Performance |
Timeline |
Blueprint Medicines Corp |
Biomarin Pharmaceutical |
Blueprint Medicines and Biomarin Pharmaceutical Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Blueprint Medicines and Biomarin Pharmaceutical
The main advantage of trading using opposite Blueprint Medicines and Biomarin Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Biomarin Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will offset losses from the drop in Biomarin Pharmaceutical's long position.Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
Biomarin Pharmaceutical vs. Alnylam Pharmaceuticals | Biomarin Pharmaceutical vs. Exelixis | Biomarin Pharmaceutical vs. Halozyme Therapeutics | Biomarin Pharmaceutical vs. Arrowhead Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Complementary Tools
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |